The SEARCH trial looked at 720 patients who were randomised 1:1 to receive either erlotinib and sorafenib or sorafenib plus placebo.
The primary endpoint of the phase III randomised, double-blind, placebo-controlled trial was a 33% increase in the overall survival on the combination treatment in comparison to sorafenib/placebo.
Personalised medicines, access to cancer drugs and to palliative care are the main issues faced by oncology patients and their healthcare professionals in Europe and worldwide, according to the organisers of the 2012 meeting of the European Society of Medical Oncology.
According to a study from Oxford University annual healthcare costs per head of population for cancer range from 32 to 165 euros across EU countries.
